How US policy volatility is redrawing global drug strategy for 2026

US regulatory and policy volatility is no longer a local issue. Shifting FDA priorities, trade policy changes and pricing pressures are rippling across global drug development — influencing investment decisions, clinical trial strategy and launch planning from Europe to Asia.

In this Pink Sheet Perspectives eBook, our expert correspondents analyse how US policy shifts are reshaping regulatory performance, regional competitiveness and market access worldwide — and what sponsors must do to stay ahead in 2026. Complete the form to access the full eBook.